Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
Main finding · Vaccine hesitancyResult — go to the resultOdds ratio 0.26 95% CI 0.24–0.30Authors' conclusion
Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
Study context
- Population
- Respondents to the international COVAD e-surveys: patients with IIM, other autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs)two survey rounds
- Exposure
- COVAD-2 vs COVAD-1; IIM vs other AIRDs, nrAIDs and HCs
- COVAD-1n = 18,882reference
- COVAD-2n = 7,666
- Outcome
- Prevalence, predictors and reasons for COVID-19 vaccine hesitancy
Methodological detailsinternational patient self-reported e-surveys, comparative analysis of two survey rounds, regression models
- International patient self-reported e-surveys
- Comparative analysis of two survey rounds
- Regression models
Main finding
Vaccine hesitancy
Odds ratio
0.26
95% CI 0.24–0.30
P < 0.001
By group
2022vs 2021
OR 0.26 (95% CI 0.24–0.30); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Skepticism over vaccine scienceIIMsvs AIRDs | 1.8 (1.08–3.2) | P = 0.023 | |
| Skepticism over vaccine scienceIIMsvs HCs | 4 (1.9–8.1) | P < 0.001 | |
| Long-term safety concerns/fearIIMsvs AIRDs | 1.9 (1.2–2.9) | P = 0.001 | |
| Long-term safety concerns/fearIIMsvs HCs | 5.4 (3–9.6) | P < 0.001 | |
| 0.10.31310Odds ratio (log scale) |
Concerns/fear over long-term safety, 2022 vs 2021
- Concerns/fear over long-term safety increased
- OR 3.6; 2.9, 4.6; P < 0.01 (95% CI, P)
Predictors of hesitancy
- Caucasians more hesitant, OR
- 4.2 (1.7-10.3) (95% CI)
- Better PROMIS physical health score less hesitant, OR
- 0.9 (0.8-0.97) (95% CI)
Original publication
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys. Rheumatology (Oxford). Published 3 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →